AB Science announces that a new independent publication confirms that masitinib has anti-vital activity against the SARS-CoV-2 virus in vitro and is a promising candidate for treating Covid-19

    NEXT STORY
    U.S. Indoor Air Quality Market
    PREV STORY
    Synairgen announces inclusion of its inhaled interferon beta treatment in US NIH ACTIV-2 trial in COVID-19 outpatients
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Translate Bio Announces Interim Results from Phase 1/2 Clinical Trial of MRT5005 in Patients with Cystic Fibrosis

    author_avatar
    NASDAQ Market News

    Iterum Therapeutics Announces Topline Results from its Phase 3 Clinical Trial of Oral Sulopenem for the Treatment of Uncomplicated Urinary Tract Infections

    author_avatar
    NASDAQ Market News

    Proximity Systems Announces New UV-Clean Self-Disinfecting Technology

    TOMBALL, Texas, Feb. 26, 2018 (GLOBE NEWSWIRE) -- Proximity Systems, Inc., the leading provider ...

    author_avatar
    NASDAQ Market News